Kamada Plasma specializes in the collection of hyperimmune human plasma and operates one of only a few specialty plasma collection centers in the United States. The center is licensed by the FDA and certified by the PPTA (Plasma Protein Therapeutics Association) and CLIA (Clinical Laboratory Improvement Amendments).
Kamada Plasma is a wholly owned subsidiary of Kamada Ltd. The center was established by Blood and Plasma Research, Inc. in 1967, and was acquired by Kamada Ltd. in 2021 as part of the company’s strategic objective of becoming a fully integrated specialty plasma company. Kamada Plasma intends to expand its plasma collection capabilities by investing in the current center and leveraging its FDA license to open additional centers in the U.S.
The collection facility mainly specializes in the collection of hyperimmune plasma used in the manufacture of Anti (D) immunoglobulin for the prevention of Hemolytic disease of the newborn, a condition arising from mismatched Rh factors between the mother and newborn. We also collect hyperimmune plasma used in the manufacture of Rabies immunoglobulin for treatment of people suspected of being exposed to a rabid animal. The center also collects specialty products from other rare donors whose blood or plasma is used in the manufacturing of blood typing reagents, diagnostic test kits for various diseases, and for research.